2 results
Approved WMOCompleted
The primary safety endpoint is to evaluate a 30-day major adverse event (MAE) rate, where MAE is a composite of the following device- or procedure-related events: * All-cause mortality* Stroke* Life-threatening bleeding (MVARC scale)* Major vascular…
Approved WMOCompleted
The objectives of the study are:* To evaluate the safety and tolerability of zilucoplan in subjects with IMNM* To evaluate the efficacy of zilucoplan in subjects with IMNM